


LGPS Central - ACS

EOS at Federated Hermes

Over the last quarter we made voting recommendations at **354** meetings (**4,197** resolutions). At **170** meetings we recommended opposing one or more resolutions. We recommended voting with management by exception at **25** meetings and abstaining at **three** meetings. We supported management on all resolutions at the remaining **156** meetings.

Global

We made voting recommendations at **354** meetings (**4,197** resolutions) over the last quarter.



- Total meetings in favour **44.1%**
- Meetings against (or against AND abstain) **48.0%**
- Meetings abstained **0.8%**
- Meetings with management by exception **7.1%**

Australia and New Zealand

We made voting recommendations at **ten** meetings (**52** resolutions) over the last quarter.



- Total meetings in favour **60%**
- Meetings against (or against AND abstain) **40%**

Developed Asia

We made voting recommendations at **56** meetings (**482** resolutions) over the last quarter.



- Total meetings in favour **53.6%**
- Meetings against (or against AND abstain) **46.4%**

Emerging and Frontier Markets

We made voting recommendations at **88** meetings (**873** resolutions) over the last quarter.



- Total meetings in favour **31.8%**
- Meetings against (or against AND abstain) **56.8%**
- Meetings abstained **2.3%**
- Meetings with management by exception **9.1%**

Europe

We made voting recommendations at **67** meetings (**902** resolutions) over the last quarter.



- Total meetings in favour **41.8%**
- Meetings against (or against AND abstain) **56.7%**
- Meetings with management by exception **1.5%**

North America


We made voting recommendations at **29** meetings (**302** resolutions) over the last quarter.



- Total meetings in favour **24.1%**
- Meetings against (or against AND abstain) **51.7%**
- Meetings with management by exception **24.1%**

United Kingdom

We made voting recommendations at **104** meetings (**1,586** resolutions) over the last quarter.



- Total meetings in favour **54.8%**
- Meetings against (or against AND abstain) **35.6%**
- Meetings abstained **1.0%**
- Meetings with management by exception **8.7%**

The issues on which we recommended voting against management or abstaining on resolutions are shown below.

Global


We recommended voting against or abstaining on **487** resolutions over the last quarter.



- Board structure **40.7%**
- Remuneration **31.2%**
- Shareholder resolution **6.0%**
- Capital structure and dividends **10.1%**
- Amend articles **3.5%**
- Audit and accounts **4.9%**
- Poison pill/Anti-takeover device **0.2%**
- Other **3.5%**

Australia and New Zealand


We recommended voting against or abstaining on **seven** resolutions over the last quarter.



- Remuneration **100%**

Developed Asia

We recommended voting against or abstaining on **53** resolutions over the last quarter.



- Board structure **66.0%**
- Remuneration **1.9%**
- Capital structure and dividends **15.1%**
- Amend articles **3.8%**
- Audit and accounts **13.2%**

Emerging and Frontier Markets

We recommended voting against or abstaining on **175** resolutions over the last quarter.



- Board structure **46.9%**
- Remuneration **21.1%**
- Shareholder resolution **4.6%**
- Capital structure and dividends **10.3%**
- Amend articles **5.7%**
- Audit and accounts **4.6%**
- Other **6.9%**

Europe

We recommended voting against or abstaining on **121** resolutions over the last quarter.



- Board structure **37.2%**
- Remuneration **34.7%**
- Shareholder resolution **0.8%**
- Capital structure and dividends **12.4%**
- Amend articles **3.3%**
- Audit and accounts **7.4%**
- Other **4.1%**

North America


We recommended voting against or abstaining on **49** resolutions over the last quarter.



- Board structure **40.8%**
- Remuneration **38.8%**
- Shareholder resolution **20.4%**

United Kingdom

We recommended voting against or abstaining on **82** resolutions over the last quarter.



- Board structure **19.5%**
- Remuneration **56.1%**
- Shareholder resolution **12.2%**
- Capital structure and dividends **9.8%**
- Amend articles **1.2%**
- Poison pill/Anti-takeover device **1.2%**